广东
分享至
BMO Capital：将BioNTech的目标价从130美元上调至143美元，维持“跑赢大盘”评级。(格隆汇)
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
